Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies
Ryan Allway
September 21st, 2021
Psychedelics
- Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round.
- Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; The Conscious Fund, Negev Capital, Ambria Capital, K2 & Associates, Empath Ventures, Supernode, Receptor Fund, and many high profiles Silicon Valley Executives.
- Mycrodose Therapeutics is widely recognized as the first company to bring Advanced Drug Delivery Technologies (ADD) into the Psychedelic Medicine Sector.
- Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT.
San Diego, California–(Newsfile Corp. – September 21, 2021) – Mycrodose Therapeutics, a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today the company has successfully completed an oversubscribed Seed Round. Proceeds from the financing will be used to expand the company’s growing patent portfolio of advanced drug delivery systems and to fund the company’s aggressive R&D milestones and preclinical initiatives on their IP-Protected transdermal & oral mucosa advanced drug delivery systems.
The company successfully closed an oversubscribed seven-figure financing round by issuing a convertible note at 8% interest to all investors. The Seed Round investment has been filled by the industry’s largest and most credible institutional investors including, The Conscious Fund, Ambria Capital, Negev Capital, K2 & Associates, Empath Ventures, Supernode, Receptor Fund, and a number of high profile high net worth Silicon Valley Executives.
“The confidence shown by investors regarding the execution capabilities of our Executive team and regarding our core technologies is humbling. The overwhelming interest to invest in our company from many of the largest and most experienced institutional investors in the Pharmaceutical and Psychedelic Sector has enabled Mycrodose to expand our original fundraising goal and strategically diversify our investor network,” said Chad Conner, Mycrodose Therapeutics’ Chief Executive Officer. “We believe that these powerful psychedelic drug compounds need to be delivered to patients in the safest and most effective method possible to minimize the potential dangers and side effects of administering an improper or unknown dosage. The many decades of experience that our team has in developing advanced drug delivery systems within the broader Pharmaceutical Industry continues to create a dominant footprint for Mycrodose in the delivery of drugs within the Psychedelic Sector.”
Mycrodose Therapeutics is widely recognized as the first company to bring Advanced Drug Delivery Technologies (ADD) into the Psychedelic Medicine Sector. Their core team has over thirty years of experience developing advanced drug delivery systems using Schedule I pharmaceutical compounds within the difficult to navigate FDA clinical environment. The company is in parallel development of two of its four core technologies; a psilocybin transdermal delivery system for treating multiple mental health indications, as well as a Ketamine oral mucosa delivery system for treatment of the oral cancer related condition known as Mucositis and other mental health indications.
The company recently completed the expansion of their state-of-the-art San Diego laboratory, which has the instrumentation needed to quantify and analyze nearly every active pharmaceutical ingredient (API) down to the millionth of a gram and determine all physicochemical parameters critical for the successful and optimum delivery of an API. The company’s core drug delivery systems each consist of various proprietary blends uniquely tailored to a specific API, including; ketamine, psilocybin, MDMA, LSD, DMT, and other compounds that improve the efficacy and stability of the final products.
Mycrodose Therapeutics believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.
Investor Quotes:
Henri Sant-Cassia, Founding Partner, The Conscious Fund
“Mycrodose is leading the evolution of drug delivery in psychedelic medicine. We are delighted to be helping their impressive team to build a company with importance to the entire sector. Their expertise and track record in creating successful exits set them apart. Ultimately, we believe their work will improve patient experiences and outcomes.”
Cody Shandraw, Director for Ambria Capital, LLC
“Mycrodose Therapeutics has everything we look for when making an investment; skilled business planning with accretive targets, a robust technology portfolio and a well-established management team. We are witnessing the evolution of the healthcare/psychedelic sector and we believe Mycrodose with their proprietary intellectual property is one of the companies leading the change. By working with the executive team at Mycrodose we’ve been able to make another meaningful investment into the future of psychedelic medicines, there’s a positive outlook for the year ahead and it’s been a great start to the year for the company.”
Ken Belotsky, Partner, Negev Capital
”Negev capital is delighted to support Mycrodose Therapeutics as they enter a new phase of development. We have invested in Mycrodose based on their impressive team, strategic vision, and tangible assets in drug delivery technology and processes…We expect the value of Mycrodose Therapeutics to increase substantially as this excellent team guides the development of innovative delivery technologies…”
Brom Rector, Founder, Empath Ventures
“Mycrodose Therapeutics has a proven team solving real problems in the psychedelics space – what more could an investor ask for? Mycrodose’s advanced psychedelic drug delivery technology has the potential to improve the patient experience, increase safety, and treat new indications. I’m grateful for the opportunity to support Mycrodose in their mission and look forward to seeing how their products impact the world of psychedelic medicine.”
Zack Sherman, General Partner, Receptor Fund
“Amid the excitement for the future of psychedelics, the importance of drug delivery is often overlooked. Advanced technologies, such as Mycrodose’s Sustained Release Ketamine Lozenge, will play a critical role in overcoming key challenges with respect to the bioavailability, dose selection and therapeutic value of psychedelic medicines.”
Jenny Friedman, Managing Partner, Supernode Ventures
“Mycrodose is in a unique position to develop advanced drug delivery technologies within the psychedelic industry. We are especially thrilled to be supporting this team of veterans focused on harnessing the safety and broadening the reach of sustained microdosing technology to children, elderly folks, and others.”
About Mycrodose Therapeutics
Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.
For more information about Mycrodose Therapeutics, please contact:
Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: Patrick@MycrodoseThera.com
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges.
The Gluu is the first ever distribution platform serving the larger cannabis industry, linking together suppliers, manufacturers, reps, retailers and customers. If you sell products think of us as the B2B Amazon of the industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
